2 results
Approved WMOCompleted
Dual Primary Objectives:* To determine if apixaban is noninferior to VKA (INR target range 2.0-3.0) on the combined endpoint of ISTHmajor or clinically relevant non-major bleeding in patients with NVAF who develop ACS or undergo PCI withplanned…
Approved WMOCompleted
Can administration of scopolaminebutyl from the start of the dying phase prevent death rattle during the dying phase?